经皮穿药盒留置术治疗中晚期肝癌  

The Treatment of Middle and Advanced Liver Cancer Using an Implantable PCS

作　　者：罗鹏飞[1] 邵培坚[1] 马壮[1] 周泽健[1] 李伟科[1] 李勇[1] 胡宝山[1] 

机构地区：[1]广东省人民医院介入室,510080

出　　处：《影像诊断与介入放射学》1996年第1期1-3,共3页Diagnostic Imaging & Interventional Radiology

摘　　要：35例中晚期肝癌病人利用左锁骨下动脉埋置的药盒,经肝动脉行长期间歇化疗灌注,采用的方案为F.A.D,即ADM60mgD1,5—FU0.5gD1—5,CDDP60mgD5,每四周重复一次,结果是一年生存率33.3％,最长一例至今已达一年半,化疗毒副作用也比经静脉的全身化疗轻。作者认为弥漫型肝癌和转移性肝癌是此一方法的良好适应症,对埋药盒的方法和并发症亦作了介绍。35 patients of non-resectable PHC 23 cases, liver metastases 12 cases were treated with F. A. D. combined hepatic infusion chemotherapy using the following regimen: ADM 60mg Dl/4w shot, 5-Fu 0. 5 Dl-5/4w shot, CDDP 60mg D5/4w shot. In every case, the catheter was placed into the hepatic artery via the left subclavian artery and an implantable portal system was used for infusion. The results were as following: 11 cases (33. 3%) survived for more than 1 year with the range of 1 - 1. 5 years. The side effects such as bone marrow supression, gastroduodenal trouble was slighter than F. A. D. regimen via iv. For the long-term catheterization in the intermittent chemotherapy, the part-catheter system (PCS) is recommended. The technique required and complications generated from the implantation were introduced in this paper.

关 键 词：肝癌 治疗 导管-药盒系统 

分 类 号：R735.705[医药卫生—肿瘤]